Boston Scientific has entered into a definitive agreement to acquire devicemaker Penumbra in a cash and stock transaction valued at approximately $14.5 billion.
Boston Scientific leaders said Penumbra’s portfolio of vascular and neurovascular technologies will expand the company’s offerings in fast-growing treatment areas, according to a Jan. 15 news release from Boston Scientific.
The acquisition is expected to close in 2026, pending shareholder and regulatory approvals.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
